Abstract
Background: Esophageal cancer (EC) causes more than 400 thousand deaths per year, and half of them occur in China. There are discrepancies regarding the survival of EC patients between population-based surveillance studies and hospital-based studies.Objectives: We aimed to synthesize the survival data from hospital-based EC studies in the Chinese population from 2000 to 2018 and to compare the survival rates between EC patients with different clinical classifications.Methods: The protocol of this systematic review was registered in PROSPERO (CRD-42019121559). We searched Embase, PubMed, CNKI, and Wanfang databases for studies published between January 1, 2000 and December 31, 2018. We calculated the pooled survival rates and 95% confidence intervals (CIs) by Stata software (V14.0).Results: Our literature search identified 933 studies, of which 331 studies with 79,777 EC patients met the inclusion criteria and were included in meta-analyses. The pooled survival rates were 74.1% (95% CI: 72.6–75.7%) for 1-year survival, 49.0% (95% CI: 44.2–53.8%) for 2-years survival, 46.0% (95% CI: 42.6–49.5%) for 3-years survival, and 40.1% (95% CI: 33.7–46.4%) for 5-years survival. An increased tendency toward EC survival was verified from 2000 to 2018. In addition, discrepancies were observed between EC patients with different clinical classifications (e.g., stages, histologic types, and cancer sites).Conclusions: Our findings showed a higher survival rate in hospital-based studies than population-based surveillance studies. Although this hospital-based study is subject to potential representability and publication bias, it offers insight into the prognosis of patients with EC in China.
Highlights
Esophageal cancer (EC) is among the top causes of cancerrelated mortality globally, resulting in more than 400 thousand deaths each year [1]
The present study aimed to systematically synthesize all eligible survival data reported in hospital-based clinical studies in the Chinese population in order to estimate the prognosis of hospitalized patients with EC
The overall pooled results were 74.1% for 1-year survival, 49.0% for 2-years survival, 46.0% for 3-years survival, and 40.1% for 5-years survival
Summary
Esophageal cancer (EC) is among the top causes of cancerrelated mortality globally, resulting in more than 400 thousand deaths each year [1]. A national screening program was launched in 2005 in areas in China with a high prevalence of EC, especially rural regions [9] This program includes endoscopic examination for high-risk individuals and early surgery in the treatment of patients with EC [5]. Many clinical investigations have reported the prognosis of patients with cancer within hospitals according to clinical research criteria These hospital-based survival investigations can reflect comprehensive treatment effectiveness with relatively lower loss to follow-up than population-based studies [15]. Discrepancies exist regarding the survival of EC patients between reports from the national cancer registry system and hospital-based studies, as well as between hospital-based studies. The present study aimed to systematically synthesize all eligible survival data reported in hospital-based clinical studies in the Chinese population in order to estimate the prognosis of hospitalized patients with EC. There are discrepancies regarding the survival of EC patients between population-based surveillance studies and hospital-based studies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
